Cristina J. Dias graduated in Biochemistry in 2015 from the University of Aveiro and completed her Master's in Biochemistry - Biomolecular Methods in 2017, also at the University of Aveiro. Throughout her academic journey, she focused on research in the field of Photobiology, particularly in the development of new porphyrinic molecules for antimicrobial and antitumoral Photodynamic Therapy. In February 2020, she participated in a short-term scientific mission at the University of Florence, Italy, contributing to the development of novel a,a'-dioxothiones molecules conjugated to porphyrin derivatives. This work, part of a COST project (COST Action 18132), resulted in a scientific paper. Cristina was also a research fellow (Dec 2018 - Jun 2020) in the PREVINE project, dedicated to innovative approaches for preventing parasitosis and associated infections in farmed fish. Her focus was on developing porphyrinic molecules for this purpose. In April and May 2023, she took part in a scientific mission at the Norwegian Radium Hospital, Oslo University Hospital, in Norway. During this internship, she had the opportunity to learn and apply a new antitumoral treatment strategy - Photochemical Internalization. Her commitment to acquiring knowledge is further exemplified through active attendance in scientific congresses and training sessions, aiming to enhance her skills. Indeed, in May-July 2023, she attended the Workshop for Histology Applied to Biomedicine organized by Universidade de Aveiro, the "Structural Glycoscience Summer School" in Grenoble, France, and completed the Practical Course in Laboratory Animal Science for Rodents organized by SPCAL at the University of Beira Interior; and in June 2024 she attended the ESP 7th Photobiology School, in Bressanone, Italy. To date, Cristina has authored/co-authored 13 scientific papers (3 as the first author), a book chapter, 14 poster communications, and 13 oral communications. In February 2025, Cristina finished her PhD in Biochemistry at the University of Aveiro. The PhD work involved the development of photoactive molecules for breast and pancreatic cancer treatment.